- Home
- ACIU vs IBEX Comparison
ACIU vs IBEX Comparison
Compare ACIU & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- IBEX
- Stock Information
- Founded
- ACIU 2003
- IBEX 2017
- Country
- ACIU Switzerland
- IBEX United States
- Employees
- ACIU N/A
- IBEX 30000
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- IBEX EDP Services
- Sector
- ACIU Health Care
- IBEX Technology
- Exchange
- ACIU Nasdaq
- IBEX Nasdaq
- Market Cap
- ACIU 332.4M
- IBEX 267.7M
- IPO Year
- ACIU 2016
- IBEX 2020
- Fundamental
- Price
- ACIU $2.68
- IBEX $20.28
- Analyst Decision
- ACIU Strong Buy
- IBEX Buy
- Analyst Count
- ACIU 2
- IBEX 4
- Target Price
- ACIU $12.00
- IBEX $21.25
- AVG Volume (30 Days)
- ACIU 134.5K
- IBEX 137.6K
- Earning Date
- ACIU 11-05-2024
- IBEX 02-06-2025
- Dividend Yield
- ACIU N/A
- IBEX N/A
- EPS Growth
- ACIU N/A
- IBEX 10.28
- EPS
- ACIU N/A
- IBEX 1.88
- Revenue
- ACIU $48,505,404.00
- IBEX $513,677,000.00
- Revenue This Year
- ACIU $85.33
- IBEX $4.89
- Revenue Next Year
- ACIU $80.69
- IBEX $4.31
- P/E Ratio
- ACIU N/A
- IBEX $10.76
- Revenue Growth
- ACIU 4097200.00
- IBEX N/A
- 52 Week Low
- ACIU $2.25
- IBEX $13.00
- 52 Week High
- ACIU $5.14
- IBEX $21.63
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- IBEX 53.20
- Support Level
- ACIU $2.62
- IBEX $19.35
- Resistance Level
- ACIU $3.02
- IBEX $20.94
- Average True Range (ATR)
- ACIU 0.13
- IBEX 0.58
- MACD
- ACIU -0.05
- IBEX -0.07
- Stochastic Oscillator
- ACIU 9.52
- IBEX 58.62
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About IBEX IBEX Limited
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.